SLI
2.047,46
PKT
+6,60
PKT
+0,32
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 13.01.23 | Zurich Insurance Overweight | JP Morgan Chase & Co. | |
| 12.01.23 | Zurich Insurance Buy | UBS AG | |
| 12.01.23 | Swiss Re Sell | UBS AG | |
| 12.01.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 12.01.23 | Nestlé Buy | Deutsche Bank AG | |
| 12.01.23 | ABB (Asea Brown Boveri) Equal Weight | Barclays Capital | |
| 11.01.23 | UBS Neutral | UBS AG | |
| 11.01.23 | UBS Buy | Goldman Sachs Group Inc. | |
| 11.01.23 | Nestlé Buy | Goldman Sachs Group Inc. | |
| 10.01.23 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 10.01.23 | Richemont Outperform | RBC Capital Markets | |
| 10.01.23 | Zurich Insurance Hold | Deutsche Bank AG | |
| 09.01.23 | Roche Neutral | UBS AG | |
| 09.01.23 | Novartis Neutral | UBS AG | |
| 09.01.23 | Richemont Buy | UBS AG | |
| 09.01.23 | Givaudan Underperform | Bernstein Research | |
| 07.01.23 | UBS Neutral | Credit Suisse Group | |
| 06.01.23 | ams-OSRAM Hold | Jefferies & Company Inc. | |
| 06.01.23 | Roche Outperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underperform | Credit Suisse Group | |
| 06.01.23 | Novartis Underweight | Morgan Stanley | |
| 06.01.23 | UBS Outperform | RBC Capital Markets | |
| 05.01.23 | UBS Overweight | JP Morgan Chase & Co. | |
| 05.01.23 | Swiss Re Sector Perform | RBC Capital Markets | |
| 05.01.23 | Richemont Market-Perform | Bernstein Research | |
| 05.01.23 | Richemont Overweight | Barclays Capital | |
| 05.01.23 | Novartis Buy | Jefferies & Company Inc. | |
| 05.01.23 | Roche Hold | Jefferies & Company Inc. | |
| 04.01.23 | ABB (Asea Brown Boveri) Hold | Deutsche Bank AG | |
| 04.01.23 | Swiss Re Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 04.01.23 | ABB (Asea Brown Boveri) Outperform | Bernstein Research | |
| 03.01.23 | Swiss Re Hold | Jefferies & Company Inc. | |
| 03.01.23 | Roche Underweight | JP Morgan Chase & Co. | |
| 03.01.23 | Novartis Neutral | JP Morgan Chase & Co. | |
| 29.12.22 | Richemont Buy | Jefferies & Company Inc. | |
| 23.12.22 | Novartis Underweight | Barclays Capital | |
| 23.12.22 | Roche Overweight | Barclays Capital | |
| 21.12.22 | UBS Outperform | RBC Capital Markets | |
| 20.12.22 | Richemont Overweight | JP Morgan Chase & Co. | |
| 20.12.22 | UBS Sector Perform | RBC Capital Markets |